Sumitomo Chemical announced on November 1 that it and its subsidiary Dainippon Sumitomo Pharma have jointly filed suit against Pfizer in the Tokyo District Court on the same day. In response to a preliminary injunction petition filed by Pfizer in October, the two companies seek a declaratory judgment that their right to manufacture and sell amoldipine besilate remains valid. Amoldipine besilate is a hypertension drug discovered by Pfizer. Since 1991, Pfizer and Sumitomo Pharamceuticals, one of the two predecessor companies of Dainippon Sumitomo Pharma, have entered into a licensing agreement for amoldipine bestilate.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=11240)